Sean P. Nolan's Insider Trades & SAST Disclosures
Sean P. Nolan's most recent trade in Ventas Inc was a trade of 2,882 Common Stock done at an average price of $64.2 . Disclosure was reported to the exchange on May 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sean P. Nolan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ventas Inc | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 64.18 per share. | 13 May 2025 | 2,882 | 24,134 (0%) | 0% | 64.2 | 184,967 | Common Stock |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 892,500 | 2,078,358 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 892,500 | 892,500 | - | - | Employee Stock Option (right to buy) | |
| Ventas Inc | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 47.96 per share. | 14 May 2024 | 3,648 | 21,252 (0%) | 0% | 48.0 | 174,958 | Common Stock |
| Taysha Gene Therapies Inc | P. Sean Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,184,688 | 1,185,858 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | P. Sean Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,184,688 | 1,184,688 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sean Nolan P. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 466,550 | 466,550 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.90 per share. | 16 Aug 2023 | 444,444 | 1,535,545 | - | 0.9 | 400,000 | Common Stock |
| Ventas Inc | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 45.63 per share. | 16 May 2023 | 3,835 | 17,604 (0%) | 0% | 45.6 | 174,991 | Common Stock |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 1,106,131 | 1,106,131 | - | - | Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Ventas Inc | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 57.25 per share. | 27 Apr 2022 | 3,056 | 13,769 (0%) | 0% | 57.3 | 174,956 | Common Stock |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Ventas Inc | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 3,158 | 10,713 (0%) | 0% | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director | Purchase of securities on an exchange or from another person at price $ 22.35 per share. | 20 May 2021 | 1,170 | 1,170 | - | 22.4 | 26,150 | Common Stock |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director | 28 Sep 2020 | 1,089,500 | 1,089,500 | - | - | Common Stock | ||
| Taysha Gene Therapies Inc | Sean P. Nolan | Director | 28 Sep 2020 | 1,000,000 | 0 | - | - | Series A Preferred Stock | ||
| Taysha Gene Therapies Inc | Sean P. Nolan | Director | 28 Sep 2020 | 1,601 | 1,091,101 | - | - | Common Stock | ||
| Taysha Gene Therapies Inc | Sean P. Nolan | Director | 28 Sep 2020 | 1,470 | 0 | - | - | Series B Preferred Stock | ||
| Taysha Gene Therapies Inc | Sean P. Nolan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2020 | 31,000 | 31,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges